| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 7296 | 2017 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2360 | 2018 |
| Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276, 2017 | 988 | 2017 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 570 | 2018 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 523 | 2021 |
| Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ... Cancer research 79 (6), 1214-1225, 2019 | 334 | 2019 |
| Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy SL Topalian, PM Forde, LA Emens, M Yarchoan, KN Smith, DM Pardoll Cancer cell 41 (9), 1551-1566, 2023 | 238 | 2023 |
| Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer V Anagnostou, N Niknafs, K Marrone, DC Bruhm, JR White, J Naidoo, ... Nature cancer 1 (1), 99-111, 2020 | 220 | 2020 |
| The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity L Danilova, V Anagnostou, JX Caushi, JW Sidhom, H Guo, HY Chan, ... Cancer immunology research 6 (8), 888-899, 2018 | 200 | 2018 |
| Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer JE Reuss, V Anagnostou, TR Cottrell, KN Smith, F Verde, M Zahurak, ... Journal for immunotherapy of cancer 8 (2), e001282, 2020 | 164 | 2020 |
| Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis F Housseau, S Wu, EC Wick, H Fan, X Wu, NJ Llosa, KN Smith, A Tam, ... Cancer research 76 (8), 2115-2124, 2016 | 153 | 2016 |
| Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ... Clinical Cancer Research 26 (6), 1327-1337, 2020 | 152 | 2020 |
| Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial PM Forde, V Anagnostou, Z Sun, SE Dahlberg, HL Kindler, N Niknafs, ... Nature medicine 27 (11), 1910-1920, 2021 | 142 | 2021 |
| Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy M Hwang, JV Canzoniero, S Rosner, G Zhang, JR White, Z Belcaid, ... Journal for immunotherapy of cancer 10 (6), e004688, 2022 | 141 | 2022 |
| Metabolic programs define dysfunctional immune responses in severe COVID-19 patients EA Thompson, K Cascino, AA Ordonez, W Zhou, A Vaghasia, ... Cell reports 34 (11), 2021 | 141 | 2021 |
| Persistent mutation burden drives sustained anti-tumor immune responses N Niknafs, A Balan, C Cherry, K Hummelink, K Monkhorst, XM Shao, ... Nature medicine 29 (2), 440-449, 2023 | 130 | 2023 |
| Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses RJ Kelly, BV Landon, AH Zaidi, D Singh, JV Canzoniero, A Balan, ... Nature medicine 30 (4), 1023-1034, 2024 | 106 | 2024 |
| Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, LS Cheung, ... The Journal of clinical investigation 131 (10), 2021 | 100 | 2021 |
| Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity BA Albert, Y Yang, XM Shao, D Singh, KN Smith, V Anagnostou, ... Nature machine intelligence 5 (8), 861-872, 2023 | 78 | 2023 |
| Five-year clinical outcomes after neoadjuvant nivolumab in resectable non–small cell lung cancer S Rosner, JE Reuss, M Zahurak, J Zhang, Z Zeng, J Taube, V Anagnostou, ... Clinical Cancer Research 29 (4), 705-710, 2023 | 77 | 2023 |
